Data On Off-Label Targeted Cancer Drugs More Plentiful Than Helpful -AHRQ
Evidence within compendia to support the off-label use of targeted cancer therapies varies widely and is rapidly evolving, making it difficult to draw solid conclusions regarding safety and efficacy, according to a draft technology assessment report released for comment by the Agency for Healthcare Research and Quality
You may also be interested in...
While health technology assessment’s role primarily is to aid clinical and policy decision-making, it also has the potential to help prioritize the comparative effectiveness research agenda as well as inform trial designs, according to a recent article in the Journal of Clinical Oncology.
FDA Commissioner Hamburg notes challenges of changing regulatory models to advance personalized medicine during AAAS/FDLI colloquium. But "we will establish a clear and illuminated pathway for product approval."
Millennium Pharmaceuticals and Ilex Oncology are hoping to launch their monoclonal antibody Campath (alemtuzumab) before the end of 2000 for treatment of B-cell chronic lymphocytic leukemia (CLL) in patients refractory to first- and second-line therapy.